Forest, TransTech sign licensing deal for diabetes drug

06/8/2010 | Wall Street Journal, The · Bloomberg Businessweek

Forest Laboratories signed a license agreement with TransTech Pharma to develop and commercialize glucose-lowering agents for diabetes. The deal, worth as much as $1.11 billion, will give Forest exclusive rights to the resulting treatment in international markets except the Middle East and North Africa, where TransTech will keep its license.

View Full Article in:

Wall Street Journal, The · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA